Myelin provides important structural, electrical, and trophic support in the central nervous system (CNS), and several diseases interfere with normal myelination, causing axonal demyelination or hypomyelination. Defects in myelination impair normal action potential propagation and dampen axonal conductivity. Remediating the conductivity between neurons in the pathological setting has proven difficult, as oligodendrocyte precursor cell (OPC) reprogramming has not, to date, been feasible on a large scale. To explore whether or not remyelination is an achievable therapeutic target in diseases such as multiple sclerosis and schizophrenia, The Scientist is bringing together a panel of experts to discuss the current body of evidence. Attendees will have the opportunity to interact with the experts, ask questions, and seek advice on topics related to their research.

Topics to be covered:

  • Promotion of remyelination by resident OPCs
  • Addressing and overcoming demyelination and hypomyelination

View the Video Now

Meet the Speakers:

Steve Goldman, MD, PhD...


Yasir Ahmed Syed, PhD
Postdoctoral Researcher
Department of Clinical Neurosciences
Cambridge Stem Cell Institute, University of Cambridge


R&D Systems

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?